Conclusions-The ratio of neutral to sialylated oligosaccharides may act as a new marker ofmalignancy in IgG paraproteinaemia and warrants further investigation. ( Clin Pathol 1998;51:825-830) 
Immunoglobulin G is enzymatically N-glycated at Asn-297 in the CH2 domain of each heavy chain.'-3 Variation in the terminal residues of each oligosaccharide leads to much heterogeneity, with up to 30 separate oligosaccharides being identified. 4 6 Crohn's disease, tuberculosis,7 and Castleman's disease. 8 The most common abnormality described is that of hypogalactosylation, in which the proportion of oligosaccharide structures bearing an outer arm galactose is reduced, with a corresponding increase in those terminating in N-acetylglucosamine (IgG GO).
Paraproteinaemia is a common finding in the population, especially with increasing age. Previous studies have indicated that the incidence of paraproteinaemia is 3% at 60 years, rising to 11.7% between the age of 80 and 90 years.9 Monoclonal paraproteins are the hallmark of malignant plasma cell disorders, but are also associated with a variety of non-myelomatous conditions. Plasma cell disorders form a spectrum of disease states ranging from the clinically benign monoclonal gammopathy of unknown significance (MGUS) to the highly malignant plasma cell leukaemias.'°T he current criteria used to differentiate MGUS from myeloma reflect the lack of a single diagnostic test to make a reliable distinction between these entities. The plasma cell labelling index (PCLI) measures the proliferation rate of plasma cells and is regarded as the best indicator of active disease, differentiating between MGUS, smouldering myeloma, and active myeloma." Serum 1-2 microglobulin, interleukin-6 (IL-6), soluble IL-6 receptor, C reactive protein, and plasma cell surface markers have all been advocated as prognostic markers in plasma cell malignancies."-'4 However, in clinical practice prolonged follow up of patients over many years may be the only certain way of identifying those with progressive disease.
There 
N5Ac, sialic acid; F, fucose; G, galactose; M, mannose; GN, N-acetylglucosamine transferase to N-acetylglucosaminyl transferase III ratio, which reflected hypogalactosylation of IgG.15 A further study by the same group identified four myeloma subjects with highly sialylated, fucosylated, and bisected biantennary sugar chains within the F(ab)2 region of their IgG paraproteins. 16 We undertook this study to determine whether change in oligosaccharide structure of IgG in multiple myeloma and MGUS is a marker malignancy and whether this can differentiate between MGUS and multiple myeloma. Immunoglobulin G paraproteins are the most common paraprotein isotype in myeloma, accounting for over 50% of patients. IgG is a glycoprotein containing two N linked oligosaccharide chains at ASN-297 in the Fc region. Previous studies have indicated that there are at least 30 possible variants, leading to much microheterogeneity.'-5 Many of the early studies on the structure of IgG were performed on IgG extracted from myeloma patients. However, in most analytical procedures IgG was pretreated with sialidase to remove terminal N-acetylneuraminic acid (sialic acid) residues in order to simplify the analytical procedure and subsequent interpretation.
Methods
Nishiura et al investigated glycoprotein changes in myeloma and reported differential binding of IgG paraproteins to the lectins concanavalin A and RCA 1 20,'5 indicating hypogalactosylation of IgG, particularly at the late stages (II and III) of myeloma, but did not, however, analyse the contribution of sialylation. There was reduced N-galactosyltransferase activity in bone marrow cells from five patients with multiple myeloma, which supported their findings. They also undertook high performance liquid chromatography (HPLC) analysis of the carbohydrate chains which were removed from the parent IgG by hydrazinolysis. However, the derivatised sugar chains were pretreated with neuraminidase to remove sialic acid before HPLC separation and so no information on sialylation was available. A further report by this group'6 indicated that in one or two patients with myeloma, highly sialylated forms of oligosaccharide could be identified.
In the present study we only studied IgG paraproteins. IgM and IgA paraproteins are described in myeloma and other lymphoproliferative disorders,23 but are less common than IgG. The glycation of IgM and IgA is far more complex than that of IgG. Immunoglobulin M exists as a pentamer with an associated J chain and has at least five N-glycation sites per heavy chain.24 Immunoglobulin A contains both N and 0 linked oligosaccharides which can be particularly numerous when it is in its dimeric form. 25 Thus it was beyond the analytical capability of the present study to analyse IgM and IgA paraproteins.
The role of sialic acid and cell surface glycoproteins in malignancy has been long debated26-28 but there have been few studies in myeloma. Frithz et al reported an increase in sialyltransferase and fucosyltransferase activities in serum in 19 untreated patients with myeloma.29 Patients at the later stages of disease showed higher activity than those at earlier stages. Six subjects followed for 20 months on treatment had a fall in sialyltransferase activity that correlated with the fall in paraprotein concentration. Patients being treated with alkylating agents and prednisolone in general had lower sialyltransferase activities. Sialyltransferase activity did not correlate with serum creatinine concentration.
Further work by Cohen et al showed an increase in sialyltransferase activity in peripheral blood mononuclear cells in 14 patients with myeloma, compared with healthy subjects and those with MGUS.30 Sialyltransferase activity was assayed in bone marrow cells (50-100% plasma cells) of five patients with myeloma and was found to be up to 19 times higher in those subjects with non-malignant disorders (plasma cells < 1.0%). Total sialic acid in mononuclear cells was measured by thiobarbituric acid (TBA) method3' and was found to be similar in all groups studied.
In a follow up study by the same group,32 sialyltransferase activity was determined in mononuclear bone marrow cells of 10 patients with myeloma and in one patient with a solitary plasmacytoma. Enzyme activity was found to be up to 12 times higher in the patients with myeloma. Activity was also increased in the plasma cells from the patient with the plasmacytoma compared with normal spleen and tonsillar tissue from the same patient.
The results of our studies support the hypothesis that increased sialylation of glycoproteins occurs in plasma cells from patients with multiple myeloma. We found that the IgG paraprotein secreted from the malignant plasma cell is more heavily sialylated in subjects with myeloma than in subjects with MGUS and in normal controls. This finding is consistent with previous reports of increased sialyltransferase activity in the mononuclear cells from such patients.2930 32 Previous workers have not been able to detect significant increases in either total serum sialic acid or mononuclear cell sialic acid concentrations. This could be explained as follows. Total serum sialic acid will measure contributions from all the serum glycoproteins, including the acute phase proteins, and this is likely to diminish any contribution from an IgG paraprotein. Secondly, previous assays used for sialic acid measurement have been relatively nonspecific and may suffer from interference.3' In this study we only measured sialylated oligosaccharides associated with IgG and by the highly sensitive and specific method of high pressure liquid chromatography with pulsed electrochemical detection. '9 The data presented here showed a significant decrease in the ratio of neutral to sialylated oligosaccharides (N:S) in myeloma. This ratio showed a progressive decrease with disease stage. All samples were analysed at the time of diagnosis and so were not affected by subsequent treatment. The sensitivity of the N:S ratio in differentiating between MGUS and myeloma was 80.4%, with a corresponding specificity of 85.7%. In contrast (-2 microglobulin had a higher sensitivity (90-100%, depending on stage) but a lower specificity (50%). The N:S ratio showed no correlation with paraprotein concentration suggesting that the extent of sialylation of IgG oligosaccharides is independent of paraprotein concentration.
In this study, C reactive protein and IL-6 performed less well than 1-2 microglobulin and the N:S ratio in terms of sensitivity and specificity in differentiating between MGUS and myeloma. The IL-6 was particularly high in stage I disease. This may have been influenced by an individual patient who had a very high IL-6 concentration of 180 ng/litre associated with a high C reactive protein of 83 mg/litre. P-2 Microglobulin was normal (0.5 mg/litre) and the patient had a survival of over 30 months on completion of the study. The N:S ratio in this individual was 5.5. It is possible that the high values for IL-6 and C reactive protein seen in this patient could be attributed to secondary infection rather than to active myeloma.
Interleukin-6 is a major plasma cell growth factor in myeloma,'3 but it also appears to have a role in the modulation of glycation of acute phase proteins. Under cell culture conditions, IL-6 stimulation of Hep 3B cells has been shown to alter the glycation patterns of the secreted proteins a-I protease inhibitor, caeruloplasmin, and a-fetoprotein.33 Nakao et al studied the potential of IL-6 to modulate glycation changes in a non-secreting human myeloma cell line.34 This group stimulated the OAM-1 cell line with IL-6 and reported a decrease in N-acetylglucosaminyl transferase III activity from these cells. They also studied cell surface oligosaccharides using FACS analysis with fluorescein isothiocyanate (FITC) labelled datura-stramonium lectin (DSL), which preferentially recognises asialotetra-antennary N linked oligosaccharides. There appeared to be increased binding of DSL to the cell surface in IL-6 stimulated cultures, indicating increased surface glycoprotein. Cells in these experiments were pretreated with sialidase to simplify analysis, and so data on sialylation are not available.
Further work by Cohen et al showed that sialyltransferase activity could be altered by both dexamethasone and recombinant interferon-a in a human myeloma cell line.35 It is apparent that cytokines such as IL-6 may modulate glycation of secreted glycoproteins in vitro; one could postulate that such modulation may occur in vivo and may reflect the changes in sialylation of IgG paraproteins that we have observed. We found no correlation between IL-6 concentration in serum and the N:S ratio on IgG.
In conclusion an increase in sialylation of IgG oligosaccharides in subjects with myeloma compared with subjects with MGUS is reported in this cross sectional study. The N:S ratio may act as an additional marker of malignancy in MM and warrants further investigation.
